COLL logo

Collegium Pharmaceutical (COLL) Company Overview

Profile

Full Name:

Collegium Pharmaceutical, Inc.

Sector:

Healthcare

Country:

United States

IPO:

May 7, 2015

Indexes:

Not included

Description:

Collegium Pharmaceutical (COLL) is a biopharmaceutical company focused on developing and commercializing innovative treatments for pain management. They create advanced drug formulations to improve patient outcomes and reduce misuse. Their products aim to provide effective relief while minimizing side effects and addiction risks.

Key Details

Price

$30.84

Annual Revenue

$566.77 M(+22.17% YoY)

Annual EPS

$1.29(+274.32% YoY)

Beta

0.64

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 4, 25 Piper Sandler
Neutral
Jan 10, 25 Needham
Buy
Jan 10, 25 HC Wainwright & Co.
Buy
Oct 11, 24 Piper Sandler
Neutral
Sep 5, 24 HC Wainwright & Co.
Buy
Aug 9, 24 Truist Securities
Buy
Aug 9, 24 Piper Sandler
Neutral
Aug 9, 24 Needham
Hold
Jul 30, 24 Needham
Hold
Jul 30, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Collegium Provides 2025 Financial Guidance and Business Update
Collegium Provides 2025 Financial Guidance and Business Update
Collegium Provides 2025 Financial Guidance and Business Update
COLL
globenewswire.comJanuary 8, 2025

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
COLL
zacks.comNovember 13, 2024

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
COLL
zacks.comNovember 8, 2024

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
COLL
seekingalpha.comNovember 8, 2024

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call.

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
COLL
zacks.comNovember 7, 2024

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
COLL
zacks.comNovember 7, 2024

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
COLL
zacks.comOctober 11, 2024

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
COLL
zacks.comSeptember 9, 2024

Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
COLL
zacks.comAugust 8, 2024

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
COLL
zacks.comAugust 8, 2024

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago.

FAQ

  • What is the ticker symbol for Collegium Pharmaceutical?
  • Does Collegium Pharmaceutical pay dividends?
  • What sector is Collegium Pharmaceutical in?
  • What industry is Collegium Pharmaceutical in?
  • What country is Collegium Pharmaceutical based in?
  • When did Collegium Pharmaceutical go public?
  • Is Collegium Pharmaceutical in the S&P 500?
  • Is Collegium Pharmaceutical in the NASDAQ 100?
  • Is Collegium Pharmaceutical in the Dow Jones?
  • When was Collegium Pharmaceutical's last earnings report?
  • When does Collegium Pharmaceutical report earnings?
  • Should I buy Collegium Pharmaceutical stock now?

What is the ticker symbol for Collegium Pharmaceutical?

The ticker symbol for Collegium Pharmaceutical is NASDAQ:COLL

Does Collegium Pharmaceutical pay dividends?

No, Collegium Pharmaceutical does not pay dividends

What sector is Collegium Pharmaceutical in?

Collegium Pharmaceutical is in the Healthcare sector

What industry is Collegium Pharmaceutical in?

Collegium Pharmaceutical is in the Drug Manufacturers - Specialty & Generic industry

What country is Collegium Pharmaceutical based in?

Collegium Pharmaceutical is headquartered in United States

When did Collegium Pharmaceutical go public?

Collegium Pharmaceutical's initial public offering (IPO) was on May 7, 2015

Is Collegium Pharmaceutical in the S&P 500?

No, Collegium Pharmaceutical is not included in the S&P 500 index

Is Collegium Pharmaceutical in the NASDAQ 100?

No, Collegium Pharmaceutical is not included in the NASDAQ 100 index

Is Collegium Pharmaceutical in the Dow Jones?

No, Collegium Pharmaceutical is not included in the Dow Jones index

When was Collegium Pharmaceutical's last earnings report?

Collegium Pharmaceutical's most recent earnings report was on Nov 7, 2024

When does Collegium Pharmaceutical report earnings?

The next expected earnings date for Collegium Pharmaceutical is Feb 21, 2025

Should I buy Collegium Pharmaceutical stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions